This is an extension study designed to provide continued treatment for eligible patients with cancer who were previously enrolled and treated in a Genentech/Roche study (the parent study), and do not have access to the treatment locally
Conditions
Brief summary
1. Number of Participants with Continued Access to Roche IMP(s)-Based Therapy and/or Comparator Agent(s)
Detailed description
1. The incidence, nature, and severity of selected adverse events as described in IMP-specific appendices
Interventions
DRUGRO7538483
DRUGINAVOLISIB
DRUGABIRATERONE
DRUGIpatasertib
DRUGTecentriq 1 200 mg concentrate for solution for infusion
DRUGAvastin 25 mg/ml concentrate for solution for infusion.
DRUGTiragolumab
DRUGRozlytrek
Sponsors
F. Hoffmann-La Roche AG
Eligibility
Sex/Gender
All
Age
18 Years to No maximum
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| 1. Number of Participants with Continued Access to Roche IMP(s)-Based Therapy and/or Comparator Agent(s) | — |
Secondary
| Measure | Time frame |
|---|---|
| 1. The incidence, nature, and severity of selected adverse events as described in IMP-specific appendices | — |
Countries
Belgium, France, Greece, Poland
Outcome results
None listed